دورية أكاديمية
أعرض في EDS

Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney.

التفاصيل البيبلوغرافية
العنوان: Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney.
المؤلفون: Simic P; Nephrology Division and.; Endocrine Unit, Endocrinology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA., Kim W; Nephrology Division and.; Endocrine Unit, Endocrinology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA., Zhou W; Nephrology Division and.; Endocrine Unit, Endocrinology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA., Pierce KA; Broad Institute, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA., Chang W; Endocrine Research Unit, San Francisco Veterans Affairs Medical Center, UCSF, San Francisco, California, USA., Sykes DB; Center for Hematology, Cancer Center, and., Aziz NB; Center for Hematology, Cancer Center, and., Elmariah S; Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA., Ngo D; Cardiovascular Research Center, Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., Pajevic PD; Department of Molecular and Cell Biology, Henry M. Goldman School of Dental Medicine, Boston University, Boston, Massachusetts, USA., Govea N; Endocrine Unit, Endocrinology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA., Kestenbaum BR; Kidney Research Institute, University of Washington Medicine and Northwest Kidney Centers, Seattle, Washington, USA., de Boer IH; Kidney Research Institute, University of Washington Medicine and Northwest Kidney Centers, Seattle, Washington, USA., Cheng Z; Endocrine Research Unit, San Francisco Veterans Affairs Medical Center, UCSF, San Francisco, California, USA., Christov M; Department of Medicine, New York Medical College, Touro College, Valhalla, New York, USA., Chun J; Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA., Leaf DE; Division of Renal (Kidney) Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Waikar SS; Renal Section, Department of Medicine, Boston University Medical Center, Boston, Massachusetts, USA., Tager AM; Division of Pulmonary and Critical Care Medicine, Department of Medicine, and., Gerszten RE; Broad Institute, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA.; Cardiovascular Research Center, Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., Thadhani RI; Nephrology Division and., Clish CB; Broad Institute, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA., Jüppner H; Endocrine Unit, Endocrinology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.; Pediatric Nephrology and Hypertension Program, Mass General for Children, Massachusetts General Hospital, Boston, Massachusetts, USA., Wein MN; Endocrine Unit, Endocrinology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA., Rhee EP; Nephrology Division and.; Endocrine Unit, Endocrinology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.; Broad Institute, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA.
المصدر: The Journal of clinical investigation [J Clin Invest] 2020 Mar 02; Vol. 130 (3), pp. 1513-1526.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
أسماء مطبوعة: Publication: 1999- : Ann Arbor, MI : American Society for Clinical Investigation
Original Publication: New Haven [etc.] American Society for Clinical Investigation.
مواضيع طبية MeSH: Acute Kidney Injury/*metabolism , Fibroblast Growth Factors/*metabolism , Glycerophosphates/*metabolism , Kidney/*metabolism, Acute Kidney Injury/genetics ; Acute Kidney Injury/pathology ; Animals ; Cell Line ; Female ; Fibroblast Growth Factor-23 ; Fibroblast Growth Factors/genetics ; Humans ; Kidney/pathology ; Male ; Metabolomics ; Mice ; Mice, Knockout ; Receptors, Lysophosphatidic Acid/genetics ; Receptors, Lysophosphatidic Acid/metabolism
مستخلص: Fibroblast growth factor 23 (FGF23) is a bone-derived hormone that controls blood phosphate levels by increasing renal phosphate excretion and reducing 1,25-dihydroxyvitamin D3 [1,25(OH)2D] production. Disorders of FGF23 homeostasis are associated with significant morbidity and mortality, but a fundamental understanding of what regulates FGF23 production is lacking. Because the kidney is the major end organ of FGF23 action, we hypothesized that it releases a factor that regulates FGF23 synthesis. Using aptamer-based proteomics and liquid chromatography-mass spectrometry-based (LC-MS-based) metabolomics, we profiled more than 1600 molecules in renal venous plasma obtained from human subjects. Renal vein glycerol-3-phosphate (G-3-P) had the strongest correlation with circulating FGF23. In mice, exogenous G-3-P stimulated bone and bone marrow FGF23 production through local G-3-P acyltransferase-mediated (GPAT-mediated) lysophosphatidic acid (LPA) synthesis. Further, the stimulatory effect of G-3-P and LPA on FGF23 required LPA receptor 1 (LPAR1). Acute kidney injury (AKI), which increases FGF23 levels, rapidly increased circulating G-3-P in humans and mice, and the effect of AKI on FGF23 was abrogated by GPAT inhibition or Lpar1 deletion. Together, our findings establish a role for kidney-derived G-3-P in mineral metabolism and outline potential targets to modulate FGF23 production during kidney injury.
التعليقات: Comment in: J Clin Invest. 2020 Mar 2;130(3):1106-1108. (PMID: 32065594)
Comment in: Nat Rev Nephrol. 2020 May;16(5):252. (PMID: 32123370)
Comment in: Kidney Int. 2020 Nov;98(5):1074-1076. (PMID: 32565191)
References: Am J Physiol Renal Physiol. 2018 Jan 1;314(1):F132-F139. (PMID: 28877877)
Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4410-5. (PMID: 23401498)
Nature. 2014 May 29;509(7502):582-7. (PMID: 24870543)
Nat Protoc. 2009;4(1):102-6. (PMID: 19131962)
Kidney Int. 2016 Apr;89(4):939-48. (PMID: 26924052)
PLoS One. 2013 Jul 29;8(7):e70941. (PMID: 23923032)
Science. 2003 Aug 1;301(5633):616-20. (PMID: 12893936)
J Bone Miner Res. 2016 Jun;31(6):1247-57. (PMID: 26792657)
Biochim Biophys Acta. 2009 Jun;1791(6):501-6. (PMID: 19038363)
J Biol Chem. 2015 Jul 3;290(27):16744-58. (PMID: 25953900)
Biology (Basel). 2014 Nov 19;3(4):801-30. (PMID: 25415055)
Am J Physiol Endocrinol Metab. 2014 Sep 1;307(5):E426-36. (PMID: 25053401)
JBMR Plus. 2018 Jan;2(1):32-47. (PMID: 29527594)
EMBO Mol Med. 2013 Mar;5(3):430-40. (PMID: 23364955)
Nature. 2006 Jan 26;439(7075):484-9. (PMID: 16400329)
Sci Rep. 2017 Jun 13;7(1):3345. (PMID: 28611350)
Bone. 2011 Sep;49(3):395-403. (PMID: 21569876)
Tissue Eng. 2001 Apr;7(2):211-28. (PMID: 11304456)
J Clin Invest. 2008 Oct;118(10):3503-12. (PMID: 18769631)
Ann Intern Med. 1999 Mar 16;130(6):461-70. (PMID: 10075613)
Circulation. 2016 Jul 26;134(4):270-85. (PMID: 27444932)
Mol Cell Biol. 2002 Dec;22(23):8204-14. (PMID: 12417724)
J Am Soc Nephrol. 2017 Jun;28(6):1877-1885. (PMID: 28028134)
Nature. 2004 May 13;429(6988):188-93. (PMID: 15141213)
J Am Soc Nephrol. 2016 Nov;27(11):3356-3367. (PMID: 27000065)
N Engl J Med. 2008 Aug 7;359(6):584-92. (PMID: 18687639)
Kidney Int. 2016 Nov;90(5):985-996. (PMID: 27457912)
Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13384-9. (PMID: 11087877)
J Am Soc Nephrol. 2017 Mar;28(3):903-914. (PMID: 28246304)
Kidney Int. 2018 May;93(5):1131-1141. (PMID: 29395333)
Clin J Am Soc Nephrol. 2018 Apr 6;13(4):531-541. (PMID: 29519954)
Nature. 2018 Jan 25;553(7689):461-466. (PMID: 29342138)
J Endocrinol. 2015 Sep;226(3):155-66. (PMID: 26148725)
Am J Physiol Regul Integr Comp Physiol. 2011 Jul;301(1):R116-30. (PMID: 21490364)
Physiol Rev. 2012 Jan;92(1):131-55. (PMID: 22298654)
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13689-94. (PMID: 9391087)
Kidney Int. 2016 Jan;89(1):135-46. (PMID: 26535997)
Arch Biochem Biophys. 2007 Sep 15;465(2):347-58. (PMID: 17689486)
J Bone Miner Res. 2013 Jan;28(1):46-55. (PMID: 22886720)
J Bone Miner Res. 2015 Mar;30(3):400-11. (PMID: 25271055)
Nature. 2014 May 8;509(7499):183-8. (PMID: 24670636)
Nat Commun. 2016 Oct 19;7:13176. (PMID: 27759007)
J Am Soc Nephrol. 2013 Jul;24(8):1330-8. (PMID: 23687356)
Biochim Biophys Acta. 2013 Jan;1831(1):105-8. (PMID: 22561288)
J Med Chem. 2009 May 28;52(10):3317-27. (PMID: 19388675)
BMC Pulm Med. 2014 Jan 27;14:5. (PMID: 24468008)
J Clin Invest. 2016 Mar 1;126(3):962-74. (PMID: 26878171)
Cell Metab. 2015 Dec 1;22(6):1020-32. (PMID: 26437603)
Circulation. 2018 Feb 20;137(8):841-853. (PMID: 29459470)
J Dent Res. 2007 Apr;86(4):320-5. (PMID: 17384025)
J Clin Invest. 2008 Jul;118(7):2526-34. (PMID: 18535668)
Nat Med. 2010 May;16(5):535-43, 1p following 143. (PMID: 20436483)
PLoS One. 2014 Mar 13;9(3):e91096. (PMID: 24625659)
J Clin Invest. 2014 Apr;124(4):1587-97. (PMID: 24569459)
J Clin Invest. 2011 Nov;121(11):4393-408. (PMID: 21985788)
J Biol Chem. 2014 Apr 4;289(14):9795-810. (PMID: 24509850)
J Clin Invest. 2012 Jul;122(7):2543-53. (PMID: 22728934)
Nat Protoc. 2013 Nov;8(11):2281-2308. (PMID: 24157548)
ChemMedChem. 2007 May;2(5):679-90. (PMID: 17443831)
Kidney Int. 2013 Oct;84(4):776-85. (PMID: 23657144)
Semin Nephrol. 2019 Jan;39(1):57-75. (PMID: 30606408)
Nat Med. 2008 Jan;14(1):45-54. (PMID: 18066075)
معلومات مُعتمدة: K08 DK124568 United States DK NIDDK NIH HHS; P30 DK040561 United States DK NIDDK NIH HHS; R01 NR017399 United States NR NINR NIH HHS; R01 DK116716 United States DK NIDDK NIH HHS; R01 DK081572 United States DK NIDDK NIH HHS; R01 AR067291 United States AR NIAMS NIH HHS; I01 BX003453 United States BX BLRD VA; U01 DK106981 United States DK NIDDK NIH HHS; R01 HL132320 United States HL NHLBI NIH HHS; R01 DK122259 United States DK NIDDK NIH HHS; IK6 BX004835 United States BX BLRD VA; P01 DK011794 United States DK NIDDK NIH HHS; R01 HL133870 United States HL NHLBI NIH HHS; K08 AR067285 United States AR NIAMS NIH HHS
فهرسة مساهمة: Keywords: Bone Biology; Bone disease; Chronic kidney disease; Homeostasis; Nephrology
المشرفين على المادة: 0 (FGF23 protein, human)
0 (Fgf23 protein, mouse)
0 (Glycerophosphates)
0 (LPAR1 protein, human)
0 (Receptors, Lysophosphatidic Acid)
0 (lysophosphatidic acid receptor 1, mouse)
62031-54-3 (Fibroblast Growth Factors)
7Q7P4S7RRE (Fibroblast Growth Factor-23)
9NTI6P3O4X (alpha-glycerophosphoric acid)
تواريخ الأحداث: Date Created: 20200218 Date Completed: 20201103 Latest Revision: 20230504
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC7269595
DOI: 10.1172/JCI131190
PMID: 32065590
قاعدة البيانات: MEDLINE
الوصف
تدمد:1558-8238
DOI:10.1172/JCI131190